The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Anal Cancer-Global Market Insights and Sales Trends 2024

Anal Cancer-Global Market Insights and Sales Trends 2024

Publishing Date : Nov, 2023

License Type :
 

Report Code : 1835886

No of Pages : 113

Ask Your Query

Synopsis
Anal cancer is a disease in which malignant (cancer) cells form in the tissues of the anus. Being infected with the human papillomavirus (HPV) increases the risk of developinganal cancer. Signs of anal cancer include bleeding from theanus or rectum or a lump near the anus.

The global Anal Cancer market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Anal Cancer in various end use industries. The expanding demands from the Hospitals, Long-Term Care Centers, Pharmacies and Other, are propelling Anal Cancer market. Fluorouracil, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Cisplatin segment is estimated at % CAGR for the next seven-year period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Objectives

This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Anal Cancer, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.

Key Features of The Study:

This report provides in-depth analysis of the global Anal Cancer market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Anal Cancer market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Anal Cancer sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Anal Cancer covered in this report include GlaxoSmithKline, Spectrum Pharmaceuticals, Hospira, Global BioPharma, Advaxis, Amgen Inc, Atara Biotherapeutics, Bayer and Cell Medica, etc.
The global Anal Cancer market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.

Market Segmentation

Company Profiles:

  • GlaxoSmithKline
  • Spectrum Pharmaceuticals
  • Hospira
  • Global BioPharma
  • Advaxis
  • Amgen Inc
  • Atara Biotherapeutics
  • Bayer
  • Cell Medica
  • Eli Lilly
  • Genticel
  • ISA Pharmaceuticals
  • Merck＆Co
  • Millennium Pharmaceuticals
  • Novartis
  • ​​Ono Pharmaceutical
  • Oryx
  • PDS Biotechnology
  • Sun Pharma

Global Anal Cancer market, by region:

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, UK, Italy, etc.)
  • Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
  • South America (Brazil, etc.)
  • Middle East and Africa (Turkey, GCC Countries, Africa, etc.)

Global Anal Cancer market, Segment by Type:

  • Fluorouracil
  • Cisplatin
  • Carboplatin
  • Other

Global Anal Cancer market, by Application

  • Hospitals
  • Long-Term Care Centers
  • Pharmacies
  • Other

Core Chapters

Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Anal Cancer companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion

Index

1 Market Overview of Anal Cancer
1.1 Anal Cancer Market Overview
1.1.1 Anal Cancer Product Scope
1.1.2 Anal Cancer Market Status and Outlook
1.2 Global Anal Cancer Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Anal Cancer Market Size by Region (2018-2029)
1.4 Global Anal Cancer Historic Market Size by Region (2018-2023)
1.5 Global Anal Cancer Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Anal Cancer Market Size (2018-2029)
1.6.1 North America Anal Cancer Market Size (2018-2029)
1.6.2 Europe Anal Cancer Market Size (2018-2029)
1.6.3 Asia-Pacific Anal Cancer Market Size (2018-2029)
1.6.4 Latin America Anal Cancer Market Size (2018-2029)
1.6.5 Middle East & Africa Anal Cancer Market Size (2018-2029)
2 Anal Cancer Market by Type
2.1 Introduction
2.1.1 Fluorouracil
2.1.2 Cisplatin
2.1.3 Carboplatin
2.1.4 Other
2.2 Global Anal Cancer Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Anal Cancer Historic Market Size by Type (2018-2023)
2.2.2 Global Anal Cancer Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Anal Cancer Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Anal Cancer Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Anal Cancer Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Anal Cancer Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Anal Cancer Revenue Breakdown by Type (2018-2029)
3 Anal Cancer Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Long-Term Care Centers
3.1.3 Pharmacies
3.1.4 Other
3.2 Global Anal Cancer Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Anal Cancer Historic Market Size by Application (2018-2023)
3.2.2 Global Anal Cancer Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Anal Cancer Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Anal Cancer Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Anal Cancer Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Anal Cancer Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Anal Cancer Revenue Breakdown by Application (2018-2029)
4 Anal Cancer Competition Analysis by Players
4.1 Global Anal Cancer Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Anal Cancer as of 2022)
4.3 Date of Key Players Enter into Anal Cancer Market
4.4 Global Top Players Anal Cancer Headquarters and Area Served
4.5 Key Players Anal Cancer Product Solution and Service
4.6 Competitive Status
4.6.1 Anal Cancer Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 GlaxoSmithKline
5.1.1 GlaxoSmithKline Profile
5.1.2 GlaxoSmithKline Main Business
5.1.3 GlaxoSmithKline Anal Cancer Products, Services and Solutions
5.1.4 GlaxoSmithKline Anal Cancer Revenue (US$ Million) & (2018-2023)
5.1.5 GlaxoSmithKline Recent Developments
5.2 Spectrum Pharmaceuticals
5.2.1 Spectrum Pharmaceuticals Profile
5.2.2 Spectrum Pharmaceuticals Main Business
5.2.3 Spectrum Pharmaceuticals Anal Cancer Products, Services and Solutions
5.2.4 Spectrum Pharmaceuticals Anal Cancer Revenue (US$ Million) & (2018-2023)
5.2.5 Spectrum Pharmaceuticals Recent Developments
5.3 Hospira
5.3.1 Hospira Profile
5.3.2 Hospira Main Business
5.3.3 Hospira Anal Cancer Products, Services and Solutions
5.3.4 Hospira Anal Cancer Revenue (US$ Million) & (2018-2023)
5.3.5 Global BioPharma Recent Developments
5.4 Global BioPharma
5.4.1 Global BioPharma Profile
5.4.2 Global BioPharma Main Business
5.4.3 Global BioPharma Anal Cancer Products, Services and Solutions
5.4.4 Global BioPharma Anal Cancer Revenue (US$ Million) & (2018-2023)
5.4.5 Global BioPharma Recent Developments
5.5 Advaxis
5.5.1 Advaxis Profile
5.5.2 Advaxis Main Business
5.5.3 Advaxis Anal Cancer Products, Services and Solutions
5.5.4 Advaxis Anal Cancer Revenue (US$ Million) & (2018-2023)
5.5.5 Advaxis Recent Developments
5.6 Amgen Inc
5.6.1 Amgen Inc Profile
5.6.2 Amgen Inc Main Business
5.6.3 Amgen Inc Anal Cancer Products, Services and Solutions
5.6.4 Amgen Inc Anal Cancer Revenue (US$ Million) & (2018-2023)
5.6.5 Amgen Inc Recent Developments
5.7 Atara Biotherapeutics
5.7.1 Atara Biotherapeutics Profile
5.7.2 Atara Biotherapeutics Main Business
5.7.3 Atara Biotherapeutics Anal Cancer Products, Services and Solutions
5.7.4 Atara Biotherapeutics Anal Cancer Revenue (US$ Million) & (2018-2023)
5.7.5 Atara Biotherapeutics Recent Developments
5.8 Bayer
5.8.1 Bayer Profile
5.8.2 Bayer Main Business
5.8.3 Bayer Anal Cancer Products, Services and Solutions
5.8.4 Bayer Anal Cancer Revenue (US$ Million) & (2018-2023)
5.8.5 Bayer Recent Developments
5.9 Cell Medica
5.9.1 Cell Medica Profile
5.9.2 Cell Medica Main Business
5.9.3 Cell Medica Anal Cancer Products, Services and Solutions
5.9.4 Cell Medica Anal Cancer Revenue (US$ Million) & (2018-2023)
5.9.5 Cell Medica Recent Developments
5.10 Eli Lilly
5.10.1 Eli Lilly Profile
5.10.2 Eli Lilly Main Business
5.10.3 Eli Lilly Anal Cancer Products, Services and Solutions
5.10.4 Eli Lilly Anal Cancer Revenue (US$ Million) & (2018-2023)
5.10.5 Eli Lilly Recent Developments
5.11 Genticel
5.11.1 Genticel Profile
5.11.2 Genticel Main Business
5.11.3 Genticel Anal Cancer Products, Services and Solutions
5.11.4 Genticel Anal Cancer Revenue (US$ Million) & (2018-2023)
5.11.5 Genticel Recent Developments
5.12 ISA Pharmaceuticals
5.12.1 ISA Pharmaceuticals Profile
5.12.2 ISA Pharmaceuticals Main Business
5.12.3 ISA Pharmaceuticals Anal Cancer Products, Services and Solutions
5.12.4 ISA Pharmaceuticals Anal Cancer Revenue (US$ Million) & (2018-2023)
5.12.5 ISA Pharmaceuticals Recent Developments
5.13 Merck＆Co
5.13.1 Merck＆Co Profile
5.13.2 Merck＆Co Main Business
5.13.3 Merck＆Co Anal Cancer Products, Services and Solutions
5.13.4 Merck＆Co Anal Cancer Revenue (US$ Million) & (2018-2023)
5.13.5 Merck＆Co Recent Developments
5.14 Millennium Pharmaceuticals
5.14.1 Millennium Pharmaceuticals Profile
5.14.2 Millennium Pharmaceuticals Main Business
5.14.3 Millennium Pharmaceuticals Anal Cancer Products, Services and Solutions
5.14.4 Millennium Pharmaceuticals Anal Cancer Revenue (US$ Million) & (2018-2023)
5.14.5 Millennium Pharmaceuticals Recent Developments
5.15 Novartis
5.15.1 Novartis Profile
5.15.2 Novartis Main Business
5.15.3 Novartis Anal Cancer Products, Services and Solutions
5.15.4 Novartis Anal Cancer Revenue (US$ Million) & (2018-2023)
5.15.5 Novartis Recent Developments
5.16 ​​Ono Pharmaceutical
5.16.1 ​​Ono Pharmaceutical Profile
5.16.2 ​​Ono Pharmaceutical Main Business
5.16.3 ​​Ono Pharmaceutical Anal Cancer Products, Services and Solutions
5.16.4 ​​Ono Pharmaceutical Anal Cancer Revenue (US$ Million) & (2018-2023)
5.16.5 ​​Ono Pharmaceutical Recent Developments
5.17 Oryx
5.17.1 Oryx Profile
5.17.2 Oryx Main Business
5.17.3 Oryx Anal Cancer Products, Services and Solutions
5.17.4 Oryx Anal Cancer Revenue (US$ Million) & (2018-2023)
5.17.5 Oryx Recent Developments
5.18 PDS Biotechnology
5.18.1 PDS Biotechnology Profile
5.18.2 PDS Biotechnology Main Business
5.18.3 PDS Biotechnology Anal Cancer Products, Services and Solutions
5.18.4 PDS Biotechnology Anal Cancer Revenue (US$ Million) & (2018-2023)
5.18.5 PDS Biotechnology Recent Developments
5.19 Sun Pharma
5.19.1 Sun Pharma Profile
5.19.2 Sun Pharma Main Business
5.19.3 Sun Pharma Anal Cancer Products, Services and Solutions
5.19.4 Sun Pharma Anal Cancer Revenue (US$ Million) & (2018-2023)
5.19.5 Sun Pharma Recent Developments
6 North America
6.1 North America Anal Cancer Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Anal Cancer Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Anal Cancer Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Anal Cancer Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Anal Cancer Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Anal Cancer Market Dynamics
11.1 Anal Cancer Industry Trends
11.2 Anal Cancer Market Drivers
11.3 Anal Cancer Market Challenges
11.4 Anal Cancer Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock